BUFEXAMAC: 56 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
56
Total FAERS Reports
54 (96.4%)
Deaths Reported
50
Hospitalizations
56
As Primary/Secondary Suspect
49
Life-Threatening
54
Disabilities
First Report: 200808 · Latest Report: 20210605
What Are the Most Common BUFEXAMAC Side Effects?
#1 Most Reported
Abdominal distension
33 reports (58.9%)
#2 Most Reported
Vomiting
32 reports (57.1%)
#3 Most Reported
Somnolence
30 reports (53.6%)
All BUFEXAMAC Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Abdominal distension | 33 | 58.9% | 33 | 28 |
| Vomiting | 32 | 57.1% | 32 | 27 |
| Abdominal pain | 30 | 53.6% | 30 | 25 |
| Appendicitis | 30 | 53.6% | 30 | 25 |
| Appendicolith | 30 | 53.6% | 30 | 25 |
| Ascites | 30 | 53.6% | 30 | 25 |
| Condition aggravated | 30 | 53.6% | 30 | 25 |
| Dyspnoea | 30 | 53.6% | 30 | 28 |
| Somnolence | 30 | 53.6% | 30 | 25 |
| Blood phosphorus increased | 29 | 51.8% | 29 | 24 |
| Dry mouth | 29 | 51.8% | 29 | 24 |
| General physical health deterioration | 29 | 51.8% | 28 | 24 |
| Hyponatraemia | 29 | 51.8% | 29 | 24 |
| Nausea | 29 | 51.8% | 29 | 24 |
| Off label use | 29 | 51.8% | 29 | 24 |
| Ventricular fibrillation | 29 | 51.8% | 29 | 24 |
| Anaemia | 28 | 50.0% | 28 | 26 |
| Blood uric acid increased | 28 | 50.0% | 28 | 26 |
| Constipation | 28 | 50.0% | 28 | 23 |
| Diabetes mellitus | 28 | 50.0% | 28 | 26 |
Who Reports BUFEXAMAC Side Effects? Age & Gender Data
Gender: 1.8% female, 98.2% male. Average age: 78.6 years. Most reports from: CA. View detailed demographics →
Is BUFEXAMAC Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2008 | 1 | 0 | 1 |
| 2020 | 20 | 20 | 19 |
| 2021 | 2 | 2 | 2 |
What Is BUFEXAMAC Used For?
| Indication | Reports |
|---|---|
| Constipation | 54 |
Official FDA Label for BUFEXAMAC
Official prescribing information from the FDA-approved drug label.